Hotspot Mutagenesis Strategy Yielding a Highly Sensitive Nanobody against Parathion for Immunoassay Development
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.5c00312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von YiFan Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, Guangzhou 510642, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Mutagenesis, Parathion. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of China, Guangdong Provincial Science and Technology Plan Project Foreign Science and Technology Cooperation Platform, Guangdong Provincial Key Laboratory of Food Quality and Safety.
Abstract (Originalsprache)
Nanobodies (Nbs) hold great potential as affinity reagents for the immunoassays of small-molecule contaminants. However, there is an urgent need for better approaches to discover higher-affinity Nbs and expand their application in food analysis. Herein, with the antiparathion nanobody (VHH9) as a model, a novel hotspot mutagenesis technique for Nb affinity maturation is reported, which targets specific motifs within Nb DNA sequences and bypasses the need for traditional 3D protein modeling to navigate candidate mutated residues. Specifically, seven residues Ser28, Tyr29, Ser32, Lys102, Phe103, Arg105, and Ala106 encoded by two AGY and two RGYW codons were selected and randomized to construct a saturation mutation library. Enhanced mutants G4, H6, and G2 were successfully isolated and then characterized by indirect competitive enzyme-linked immunosorbent assay (ic-ELISA), with half-maximal inhibition concentrations (IC50) of 4.7, 3.5, and 2.9 ng/mL, respectively, 2.1-, 2.9-, and 3.5-fold lower than that of the original Nbs. Subsequently, a biotin-streptavidin-amplified ELISA (BA-ELISA) was developed for the detection of parathion based on biotinylated H6. The developed BA-ELISA showed an IC50 value as low as 1.5 ng/mL, which was 2.3-fold improvement in sensitivity compared to H6-based ic-ELISA. The average recoveries in vegetable and fruit samples ranged from 87.0% to 113.0%. In summary, this work demonstrated that hotspot mutagenesis is effective for maximizing the efficiency to obtain Nbs with improved sensitivity, and the developed BA-ELISA is a robust tool for the routine screening of parathion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, Guangzhou 510642, China.
- Guangzhou Institute of Food Inspection, Guangzhou 510080, China.
ORCID-Profile: Zhen-Lin Xu, Hong Wang
Förderung
- Natural Science Foundation of China
- Guangdong Provincial Science and Technology Plan Project Foreign Science and Technology Cooperation Platform
- Guangdong Provincial Key Laboratory of Food Quality and Safety
- Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme
Zitieren
APA
Liang, Y., Chen, X., Fang, R. Y., Feng, T. H., Chen, Y., Xu, Z. L., Shen, Y. D., Yang, J., & Wang, H. (2025). Hotspot Mutagenesis Strategy Yielding a Highly Sensitive Nanobody against Parathion for Immunoassay Development. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.5c00312
Vancouver
Liang Y, Chen X, Fang RY, Feng TH, Chen Y, Xu ZL, et al. Hotspot Mutagenesis Strategy Yielding a Highly Sensitive Nanobody against Parathion for Immunoassay Development. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.5c00312
BibTeX
@article{Liang2025,
author = {Liang, YiFan and Chen, Xiao and Fang, Ru-Yu and Feng, Tian-Hui and Chen, YanHong and Xu, Zhen-Lin and Shen, Yu-Dong and Yang, JinYi and Wang, Hong},
title = {Hotspot Mutagenesis Strategy Yielding a Highly Sensitive Nanobody against Parathion for Immunoassay Development},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.5c00312}
}
EUVIMED